Study identifier:D3560L00039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicentre Study Comparing the Efficacy of Rosuvastatin with Atorvastatin When Given for a Period of 16 Wks to Subjects with Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention
Coronary heart disease
Phase 4
No
Rosuvastatin or atorvastatin or simvastatin and clopidogrel
All
255
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: None
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of treatment in patients with coronary heart disease
Location
Location
Danderyd, Sweden
Location
EKSJÖ, Sweden
Location
FALUN, Sweden
Location
GÖTEBORG, Sweden
Location
Helsingborg, Sweden
Location
JÖNKÖPING, Sweden
Location
Karlskrona, Sweden
Location
Karlstad, Sweden
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.